Home › Companies › Solid Biosciences Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Solid Biosciences Inc.’s Form 8-K, filed June 10, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 10, 2026: 7 items on Solid Biosciences Inc.’s Form 8-K, filed June 10, 2026: 3 elected · 4 approved.
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Ra Capital Management, L.P. (13D, 10.8%, as of November 6, 2026)
Explore Solid Biosciences Inc. in the interactive database Compare manager voting policies
These tallies are Solid Biosciences Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Clare Kahn | 73,139,200 | -- | -- | 5,700,169 | 7,685,551 | 93% | Elected | — |
| Elect Director: Adam Stone | 71,556,735 | -- | -- | 7,282,634 | 7,685,551 | 91% | Elected | — |
| Elect Director: Lynne Sullivan | 73,124,331 | -- | -- | 5,715,038 | 7,685,551 | 93% | Elected | — |
| 2. The appointment of Ilan Ganot, on an advisory basis, as a Class I director to serve until the 2028 Annual Meeting of Stockholders | 78,636,398 | 185,585 | 17,386 | -- | 7,685,551 | 99.8% | Approved | — |
| 3. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 86,420,186 | 70,007 | 34,727 | -- | -- | 99.9% | Approved | — |
| 4. An amendment to the Company's Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's common stock from 240,000,000 to 480,000,000 (the "Share Increase Amendment") | 85,604,508 | 893,360 | 27,502 | -- | -- | 99% | Approved | — |
| 5. Non-binding, advisory vote on the compensation paid to its named executive officers | 72,596,980 | 6,203,634 | 38,755 | -- | 7,685,551 | 92% | Approved | — |
Source: Solid Biosciences Inc., Form 8-K, filed with the SEC on June 10, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
150 asset managers disclosed a vote on at least one Solid Biosciences Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Adam Stone
Solid Biosciences Inc.’s own tally for this item (“Elect Director: Adam Stone”): 71,556,735 for, 7,282,634 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected Clare Kahn, Adam Stone and Lynne Sullivan as Class II directors to serve until the 2029 Annual Meeting of Stockholders, each director to hold office until his or her successor has been duly appointed and qualified.”
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 44 asset managers below reported 13,357,348 for, 591,259 withheld, 7 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,839,219 | 0 | 0 | 0 | For |
| Vanguard | 2,980,065 | 0 | 7 | 5,422 | For |
| Columbia Threadneedle | 1,595,479 | 0 | 0 | 0 | For |
| BlackRock | 1,487,648 | 0 | 0 | 44,895 | For |
| FRANKLIN STRATEGIC SERIES | 1,253,978 | 0 | 0 | 0 | For |
| TIAA | 387,214 | 0 | 0 | 0 | For |
| Invesco | 231,907 | 0 | 0 | 0 | For |
| Charles Schwab | 160,725 | 0 | 0 | 0 | For |
| Equitable | 97,235 | 0 | 0 | 52,080 | Mixed |
| American Century | 0 | 0 | 0 | 114,392 | Withhold |
| Dimensional | 0 | 0 | 0 | 97,394 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 97,015 | 0 | 0 | 0 | For |
| JPMorgan | 94,041 | 0 | 0 | 0 | For |
| Lincoln Financial | 20,678 | 0 | 0 | 64,078 | Mixed |
| Northern Trust | 0 | 0 | 0 | 29,404 | Withhold |
| Global X | 28,094 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 27,766 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 23,575 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 0 | 22,095 | Withhold |
| Pacific Life | 21,916 | 0 | 0 | 0 | For |
| Nationwide | 16,998 | 0 | 0 | 2,409 | Mixed |
| State Street | 0 | 0 | 0 | 19,329 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 15,000 | Withhold |
| Jackson National | 0 | 0 | 0 | 13,761 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 11,390 | Withhold |
Showing the 25 largest of 44 asset managers. All 44 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Clare Kahn
Solid Biosciences Inc.’s own tally for this item (“Elect Director: Clare Kahn”): 73,139,200 for, 5,700,169 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected Clare Kahn, Adam Stone and Lynne Sullivan as Class II directors to serve until the 2029 Annual Meeting of Stockholders, each director to hold office until his or her successor has been duly appointed and qualified.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 44 asset managers below reported 13,540,791 for, 407,817 withheld, 6 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,839,219 | 0 | 0 | 0 | For |
| Vanguard | 2,981,826 | 0 | 6 | 3,662 | For |
| Columbia Threadneedle | 1,595,479 | 0 | 0 | 0 | For |
| BlackRock | 1,532,543 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,253,978 | 0 | 0 | 0 | For |
| TIAA | 387,214 | 0 | 0 | 0 | For |
| Invesco | 231,907 | 0 | 0 | 0 | For |
| Charles Schwab | 160,725 | 0 | 0 | 0 | For |
| Equitable | 97,235 | 0 | 0 | 52,080 | Mixed |
| American Century | 0 | 0 | 0 | 114,392 | Withhold |
| Dimensional | 0 | 0 | 0 | 97,394 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 97,015 | 0 | 0 | 0 | For |
| JPMorgan | 94,041 | 0 | 0 | 0 | For |
| Lincoln Financial | 57,278 | 0 | 0 | 27,478 | Mixed |
| Northern Trust | 29,404 | 0 | 0 | 0 | For |
| Global X | 28,094 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 27,766 | 0 | 0 | 0 | For |
| Voya | 23,575 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,095 | 0 | 0 | 0 | For |
| Pacific Life | 21,916 | 0 | 0 | 0 | For |
| Nationwide | 19,407 | 0 | 0 | 0 | For |
| State Street | 19,329 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 15,000 | Withhold |
| Jackson National | 0 | 0 | 0 | 13,761 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 11,390 | Withhold |
Showing the 25 largest of 44 asset managers. All 44 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Lynne Sullivan
Solid Biosciences Inc.’s own tally for this item (“Elect Director: Lynne Sullivan”): 73,124,331 for, 5,715,038 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected Clare Kahn, Adam Stone and Lynne Sullivan as Class II directors to serve until the 2029 Annual Meeting of Stockholders, each director to hold office until his or her successor has been duly appointed and qualified.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 44 asset managers below reported 13,539,031 for, 409,577 withheld, 6 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,839,219 | 0 | 0 | 0 | For |
| Vanguard | 2,980,066 | 0 | 6 | 5,422 | For |
| Columbia Threadneedle | 1,595,479 | 0 | 0 | 0 | For |
| BlackRock | 1,532,543 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,253,978 | 0 | 0 | 0 | For |
| TIAA | 387,214 | 0 | 0 | 0 | For |
| Invesco | 231,907 | 0 | 0 | 0 | For |
| Charles Schwab | 160,725 | 0 | 0 | 0 | For |
| Equitable | 97,235 | 0 | 0 | 52,080 | Mixed |
| American Century | 0 | 0 | 0 | 114,392 | Withhold |
| Dimensional | 0 | 0 | 0 | 97,394 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 97,015 | 0 | 0 | 0 | For |
| JPMorgan | 94,041 | 0 | 0 | 0 | For |
| Lincoln Financial | 57,278 | 0 | 0 | 27,478 | Mixed |
| Northern Trust | 29,404 | 0 | 0 | 0 | For |
| Global X | 28,094 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 27,766 | 0 | 0 | 0 | For |
| Voya | 23,575 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,095 | 0 | 0 | 0 | For |
| Pacific Life | 21,916 | 0 | 0 | 0 | For |
| Nationwide | 19,407 | 0 | 0 | 0 | For |
| State Street | 19,329 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 15,000 | Withhold |
| Jackson National | 0 | 0 | 0 | 13,761 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 11,390 | Withhold |
Showing the 25 largest of 44 asset managers. All 44 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: The ratification of the appointment of Ilan Ganot, on an advisory basis, to the Company's Board of Directors as a Class I Director to hold office until the 2028 annual meeting of stockholders.
Solid Biosciences Inc.’s own tally for this item (“2. The appointment of Ilan Ganot, on an advisory basis, as a Class I director to serve until the 2028 Annual Meeting of Stockholders”): 78,636,398 for, 185,585 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Ilan Ganot, on an advisory basis, as a Class I director to serve until the 2028 Annual Meeting of Stockholders.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 44 asset managers below reported 13,944,952 for, 3,662 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,839,219 | 0 | 0 | 0 | For |
| Vanguard | 2,981,832 | 3,662 | 0 | 0 | For |
| Columbia Threadneedle | 1,595,479 | 0 | 0 | 0 | For |
| BlackRock | 1,532,543 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,253,978 | 0 | 0 | 0 | For |
| TIAA | 387,214 | 0 | 0 | 0 | For |
| Invesco | 231,907 | 0 | 0 | 0 | For |
| Charles Schwab | 160,725 | 0 | 0 | 0 | For |
| Equitable | 149,315 | 0 | 0 | 0 | For |
| American Century | 114,392 | 0 | 0 | 0 | For |
| Dimensional | 97,394 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 97,015 | 0 | 0 | 0 | For |
| JPMorgan | 94,041 | 0 | 0 | 0 | For |
| Lincoln Financial | 84,756 | 0 | 0 | 0 | For |
| Northern Trust | 29,404 | 0 | 0 | 0 | For |
| Global X | 28,094 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 27,766 | 0 | 0 | 0 | For |
| Voya | 23,575 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,095 | 0 | 0 | 0 | For |
| Pacific Life | 21,916 | 0 | 0 | 0 | For |
| Nationwide | 19,407 | 0 | 0 | 0 | For |
| State Street | 19,329 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 15,000 | 0 | 0 | 0 | For |
| Jackson National | 13,761 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 11,390 | 0 | 0 | 0 | For |
Showing the 25 largest of 44 asset managers. All 44 are in the interactive database (link above).
99% Approved · of votes cast
Description as filed by funds: The approval of an amendment to the Company's Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's common stock from 240,000,000 to 480,000,000.
Solid Biosciences Inc.’s own tally for this item (“4. An amendment to the Company's Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's common stock from 240,000,000 to 480,000,000 (the "Share Increase Amendment")”): 85,604,508 for, 893,360 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved an amendment to the Company's Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's common stock from 240,000,000 to 480,000,000 (the "Share Increase Amendment").”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 44 asset managers below reported 13,948,613 for, 1 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,839,219 | 0 | 0 | 0 | For |
| Vanguard | 2,985,493 | 1 | 0 | 0 | For |
| Columbia Threadneedle | 1,595,479 | 0 | 0 | 0 | For |
| BlackRock | 1,532,543 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,253,978 | 0 | 0 | 0 | For |
| TIAA | 387,214 | 0 | 0 | 0 | For |
| Invesco | 231,907 | 0 | 0 | 0 | For |
| Charles Schwab | 160,725 | 0 | 0 | 0 | For |
| Equitable | 149,315 | 0 | 0 | 0 | For |
| American Century | 114,392 | 0 | 0 | 0 | For |
| Dimensional | 97,394 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 97,015 | 0 | 0 | 0 | For |
| JPMorgan | 94,041 | 0 | 0 | 0 | For |
| Lincoln Financial | 84,756 | 0 | 0 | 0 | For |
| Northern Trust | 29,404 | 0 | 0 | 0 | For |
| Global X | 28,094 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 27,766 | 0 | 0 | 0 | For |
| Voya | 23,575 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,095 | 0 | 0 | 0 | For |
| Pacific Life | 21,916 | 0 | 0 | 0 | For |
| Nationwide | 19,407 | 0 | 0 | 0 | For |
| State Street | 19,329 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 15,000 | 0 | 0 | 0 | For |
| Jackson National | 13,761 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 11,390 | 0 | 0 | 0 | For |
Showing the 25 largest of 44 asset managers. All 44 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
92% Approved · of votes cast
Prior year: 91.7% for (June 12, 2025 meeting) ▲ 0.4 pts
Description as filed by funds: THE APPROVAL OF AN ADVISORY VOTE ON EXECUTIVE COMPENSATION.
Solid Biosciences Inc.’s own tally for this item (“5. The non-binding, advisory vote on the compensation paid to its named executive officers”): 72,596,980 for, 6,203,634 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,839,219 | 0 | 0 | 0 | For |
| Vanguard | 2,985,488 | 6 | 0 | 0 | For |
| Columbia Threadneedle | 1,595,479 | 0 | 0 | 0 | For |
| BlackRock | 1,532,543 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,253,978 | 0 | 0 | 0 | For |
| TIAA | 387,214 | 0 | 0 | 0 | For |
| Invesco | 0 | 231,907 | 0 | 0 | Against |
| Charles Schwab | 160,725 | 0 | 0 | 0 | For |
| Equitable | 97,235 | 52,080 | 0 | 0 | Mixed |
| American Century | 0 | 114,392 | 0 | 0 | Against |
| Dimensional | 0 | 97,394 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 97,015 | 0 | 0 | 0 | For |
| JPMorgan | 94,041 | 0 | 0 | 0 | For |
| Lincoln Financial | 57,278 | 27,478 | 0 | 0 | Mixed |
| Northern Trust | 29,404 | 0 | 0 | 0 | For |
| Global X | 28,094 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 27,766 | 0 | 0 | 0 | For |
| Voya | 0 | 23,575 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 22,095 | 0 | 0 | 0 | For |
| Pacific Life | 21,916 | 0 | 0 | 0 | For |
| Nationwide | 19,407 | 0 | 0 | 0 | For |
| State Street | 19,329 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 15,000 | 0 | 0 | Against |
| Jackson National | 0 | 13,761 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 11,390 | 0 | 0 | Against |
Fund voting reports, all 44 managers: 13,309,711 for, 638,903 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 11,055,900 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 9,339,978 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 7,690,405 | 0 | 0 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 4,505,922 | 0 | 0 | 0 | For |
| Fidelity | 3,730,575 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 3,565,062 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 2,649,449 | 22,467 | 0 | 0 | For |
| Vestal Point Capital, LP | 0 | 2,505,604 | 0 | 0 | Against |
| Redmile Group, LLC | 1,948,695 | 0 | 0 | 0 | For |
| BlackRock | 1,792,854 | 11,607 | 0 | 0 | For |
| Alyeska Investment Group, L.P. | 1,652,985 | 0 | 0 | 0 | For |
| Citadel | 1,386,584 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,304,495 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 582,400 | 537,600 | 0 | 0 | Mixed |
| State Street | 933,646 | 7,056 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 550,935 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0 | 535,377 | 0 | 0 | Against |
| Woodline Partners LP | 479,795 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 478,889 | 0 | 0 | 0 | For |
| BLAIR WILLIAM & CO/IL | 0 | 441,200 | 0 | 0 | Against |
| Nuveen | 400,292 | 0 | 0 | 0 | For |
| Vanguard | 362,451 | 4,783 | 0 | 0 | For |
| Ally Bridge Group (NY) LLC | 358,257 | 0 | 0 | 0 | For |
| Northern Trust | 312,698 | 9,174 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 277,363 | 0 | 0 | 0 | For |
Institutional-manager reports, all 120 managers: 56,219,653 for, 5,304,982 against, 94 not voted. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Prior year: 100.0% for (June 12, 2025 meeting) unchanged
Description as filed by funds: The ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Solid Biosciences Inc.’s own tally for this item (“3. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 86,420,186 for, 70,007 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 44 asset managers below reported 13,948,614 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,839,219 | 0 | 0 | 0 | For |
| Vanguard | 2,985,494 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 1,595,479 | 0 | 0 | 0 | For |
| BlackRock | 1,532,543 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,253,978 | 0 | 0 | 0 | For |
| TIAA | 387,214 | 0 | 0 | 0 | For |
| Invesco | 231,907 | 0 | 0 | 0 | For |
| Charles Schwab | 160,725 | 0 | 0 | 0 | For |
| Equitable | 149,315 | 0 | 0 | 0 | For |
| American Century | 114,392 | 0 | 0 | 0 | For |
| Dimensional | 97,394 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 97,015 | 0 | 0 | 0 | For |
| JPMorgan | 94,041 | 0 | 0 | 0 | For |
| Lincoln Financial | 84,756 | 0 | 0 | 0 | For |
| Northern Trust | 29,404 | 0 | 0 | 0 | For |
| Global X | 28,094 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 27,766 | 0 | 0 | 0 | For |
| Voya | 23,575 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,095 | 0 | 0 | 0 | For |
| Pacific Life | 21,916 | 0 | 0 | 0 | For |
| Nationwide | 19,407 | 0 | 0 | 0 | For |
| State Street | 19,329 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 15,000 | 0 | 0 | 0 | For |
| Jackson National | 13,761 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 11,390 | 0 | 0 | 0 | For |
Showing the 25 largest of 44 asset managers. All 44 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 98,449,606 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 4.92% |
| 2 | Vanguard | 3.03% |
| 3 | Columbia Threadneedle | 1.62% |
| 4 | BlackRock | 1.56% |
| 5 | FRANKLIN STRATEGIC SERIES | 1.27% |
| 6 | TIAA | 0.39% |
| 7 | Invesco | 0.24% |
| 8 | Charles Schwab | 0.16% |
| 9 | Equitable | 0.15% |
| 10 | American Century | 0.12% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | 11.23% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 9.49% |
| 3 | Siren, L.L.C. | 7.81% |
| 4 | Bain Capital Life Sciences Investors, LLC | 4.58% |
| 5 | Fidelity | 3.79% |
| 6 | Deep Track Capital, LP | 3.62% |
| 7 | FRANKLIN ADVISERS INC | 2.71% |
| 8 | Vestal Point Capital, LP | 2.55% |
| 9 | Redmile Group, LLC | 1.98% |
| 10 | BlackRock | 1.83% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| RA Capital Management, L.P. | 12,036,126 | 12.23% | Schedule 13D, filed June 24, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. and affiliated entities | 11,969,078 | 12.16% | Proxy statement (DEF 14A), table as of April 16, 2026 |
| Entities affiliated with Bain Capital Life Sciences Investors, LLC | 10,420,499 | 10.58% | Proxy statement (DEF 14A), table as of April 16, 2026 |
| Invus Public Equities, L.P. and affiliated entities | 10,067,060 | 10.23% | Proxy statement (DEF 14A), table as of April 16, 2026 |
| Raymond Debbane | 10,066,682 | 10.23% | Schedule 13G, filed May 5, 2026 |
| Entities affiliated with RA Capital Management, L.P. | 9,925,435 | 10.08% | Proxy statement (DEF 14A), table as of April 16, 2026 |
| Entities associated with Vestal Point Capital, LP | 9,463,812 | 9.61% | Proxy statement (DEF 14A), table as of April 16, 2026 |
| BCLS II Investco, LP | 8,604,852 | 8.74% | Schedule 13D, filed March 10, 2026 |
| BlackRock | 4,958,354 | 5.04% | Form 13F, quarter ended March 31, 2026 |
| Vestal Point Capital, LP | 4,833,796 | 4.91% | Schedule 13G, filed August 14, 2026 |
Percentages above are of 98,449,606 shares outstanding, as reported by Solid Biosciences Inc. on its Form 10-Q dated May 8, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Solid Biosciences Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 150 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 971 separate fund positions. On the most widely held item on that ballot — THE APPROVAL OF AN ADVISORY VOTE ON EXECUTIVE COMPENSATION. — Solid Biosciences Inc.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Solid Biosciences Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Solid Biosciences Inc.’s 10-Q dated May 8, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Solid Biosciences Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Solid Biosciences (SLDB) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/solid-biosciences-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.